5 Things You Need to Know If You Buy Viking Therapeutics Stock Today
What's the hottest biotech stock on the market right now? If we limit the list only to those with market caps of at least $500 million, it's Viking Therapeutics (NASDAQ: VKTX). So far in 2024, Viking's shares have skyrocketed over 270% (and were up even higher at points).
Is it too late for investors to jump aboard the Viking bandwagon? I don't think so. Here are five things you need to know if you buy Viking Therapeutics stock today.
Viking's impressive year-to-date stock performance is due to excitement about the prospects of its experimental drug VK2735. In February, the company reported overwhelmingly positive top-line results from the phase 2 Venture clinical trial evaluating the dual GLP-1/GIP receptor agonist in patients with obesity.
Source Fool.com
Viking Therapeutics Inc Aktie
Viking Therapeutics Inc erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Für Viking Therapeutics Inc ergibt sich mit einem Kursziel von 110 € eine mögliche Steigerung von über 50% gegenüber 56.72 €.
